Study Methods Influence Estimates Of Lead Time And Overdiagnosis In Prostate Cancer

In prostate cancer, estimates of lead time (how long screening advances diagnosis of cancer) and overdiagnosis (the fraction of cancers detected by screening that would not have been diagnosed during the patient’s lifetime without screening) vary widely, depending on the definition of lead time used, the population, and the estimation methodology, according to a report in the March 10 online issue of the Journal of the National Cancer Institute.

More: continued here

Filed under: Cancer on March 11th, 2009